Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
Publication in refereed journal


香港中文大学研究人员 ( 现职)

莫树锦教授 (肿瘤学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1016/j.lungcan.2014.05.007

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/23WOS source URL

其它资讯

摘要Objectives: Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment with EGFR tyrosine kinase inhibitors (TKIs). Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. We aimed to assess the relative efficacy of the three drugs by conducting a network meta-analysis (NMA).

着者Popat S, Mok T, Yang JCH, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L
期刊名称Lung Cancer
出版年份2014
月份8
日期1
卷号85
期次2
出版社Elsevier
页次http://aims.cuhk.edu.hk/converis/portal/Publication/230 - http://aims.cuhk.edu.hk/converis/portal/Publication/238
国际标準期刊号0169-5002
电子国际标準期刊号1872-8332
语言英式英语

关键词Afatinib; Chemotherapy; Epidermal growth factor receptor (EGFR); Erlotinib; Gefitinib; NSCLC; Tyrosine kinase inhibitor
Web of Science 学科类别Oncology; ONCOLOGY; Respiratory System; RESPIRATORY SYSTEM